Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage (DASH)

NCT03696121 is registered in ClinicalTrials.gov with University of Nottingham as lead sponsor.

NCT NCT03696121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03696121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage (DASH)
Lead sponsor
University of Nottingham
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2019
Completion date
June 30, 2022
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stroke, acute